Bioheng Biotech Raises $ 80 Million in Series B Funding
Bioheng Biotech Co., Ltd., a Nanjing, China-based clinical-stage biotechnology company focused on developing a novel cell-based immunotherapy for cancer, has raised $ 80 million in Series B funding.
The round was co-led by GL Ventures, the venture capital unit of Hillhouse Capital, Decheng Capital and Octagon Capital, with participation from BlueRun Ventures China and Shenzhen Capital Group Company.
The company intends to use the funds to advance R&D capabilities, process development and clinical trials.
Led by Dr. Xiaohong He, Founder and CEO, Bioheng is a clinical-stage biotechnology company focused on the development and commercialization of novel allogeneic cell immunotherapy for the immediate treatment of cancer patients, this which can increase affordability and accessibility by overcoming obstacles encountered. by autologous cell therapy. The company has set up an allogeneic immunotherapy platform and built a 75,000 square foot high-level GMP translation center and manufacturing plant, which is equipped with a complete closed and semi-automated production system. Complies with NMPA and FDA regulatory guidelines.